دورية أكاديمية
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer
| العنوان: | Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer |
|---|---|
| المؤلفون: | Cappel, WHDN, Meulenbeld, HJ, Kleibeuker, JH, Nagengast, FM, Menko, FH, Griffioen, G, Cats, A, Morreau, H, Gelderblom, H, Vasen, HFA |
| المصدر: | Cappel , WHDN , Meulenbeld , HJ , Kleibeuker , JH , Nagengast , FM , Menko , FH , Griffioen , G , Cats , A , Morreau , H , Gelderblom , H & Vasen , HFA 2004 , ' Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer ' , International Journal of Cancer , vol. 109 , no. 3 , pp. 468-471 . https://doi.org/10.1002/ijc.11712Test |
| سنة النشر: | 2004 |
| المجموعة: | University of Groningen research database |
| مصطلحات موضوعية: | HNPCC, colorectal cancer, MMR, 5FU, MICROSATELLITE INSTABILITY, CHEMOTHERAPY, 5-FLUOROURACIL, LYMPHOCYTES, LEVAMISOLE |
| الوصف: | In vitro studies suggest that a deficient mismatch repair (MMR) system-reduces 5-Fluorouracil cytotoxicity. Colon cancer (CC) in hereditary nonpolyposis colorectal cancer (HNPCC) is due to a dysfunctioning MMR gene that leads to microsatellite instability (MSI). Clinical studies on the efficacy of 5-Fluorouracil (5-FU) in MSI high tumours are contradictory. In a retrospective study, we compared the survival of subjects with stage III CC from HNPCC families that were treated with and without adjuvant 5-FU. The Dutch HNPCC family registry was used. Information on adjuvant chemotherapy for stage III CC was obtained from subjects of families with a mutation and/or who fulfilled the AMS criteria or who were strongly suspicious for HNPCC. CC specific survival was calculated. Observation time was measured either until the date of death, date of a second primary CC or until the closing date of the study, i.e., June 1, 2001. Statistical analysis was done by Kaplan-Meier survival analysis. A total of 92 subjects with stage III CC were included. Twenty-eight of them (17 males) had adjuvant treatment with 5-FU. The median follow-up was 4 (range: 1-17) years; 8 subjects died of CC. The 5-year survival was 70% (95% Cl: 49-90). Sixty-four subjects (36 males) did not have adjuvant therapy. Their median follow-up was 6 (range: 0-23) years. Twenty of them died of CC. The 5-year survival in this group was also 70% (95% CI: 59-83). To date, the selection of patients with CC for 5-FU treatment is based on the stage rather than the biology of the tumour. In our study, the 5-year survival of subjects treated with and without adjuvant 5-FU did not differ. Further studies are necessary to elucidate the role of MSI in 5-FU treatment of MSI-H tumours in HNPCC. (C) 2004 Wiley-Liss, Inc. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://research.rug.nl/en/publications/fa092ce0-ccfb-467a-b988-1999f085f5e5Test |
| DOI: | 10.1002/ijc.11712 |
| الإتاحة: | https://doi.org/10.1002/ijc.11712Test https://hdl.handle.net/11370/fa092ce0-ccfb-467a-b988-1999f085f5e5Test https://research.rug.nl/en/publications/fa092ce0-ccfb-467a-b988-1999f085f5e5Test |
| حقوق: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.92EEC5EC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/ijc.11712 |
|---|